Drug fusions and conjugates with extended half life

Details for Australian Patent Application No. 2010303112 (hide)

Owner Glaxo Group Limited

Inventors Hamilton, Bruce; Herring, Christopher; Paulik, Mark Andrew

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2010303112

PCT Pub. Number WO2011/039096

Priority 61/247,346 30.09.09 US

Filing date 23 September 2010

Wipo publication date 7 April 2011

International Classifications

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 3/08 (2006.01) Drugs for disorders of the metabolism

A61P 5/48 (2006.01) Drugs for disorders of the endocrine system

C07K 14/575 (2006.01) Peptides having more than 20 amino acids

C07K 14/605 (2006.01) Peptides having more than 20 amino acids

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

26 April 2012 PCT application entered the National Phase

  PCT publication WO2011/039096 Priority application(s): WO2011/039096

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010303117-Lockable quick coupling

2010303108-Spring arrangement for controlling the ride in a vehicle